What do Canadian hematologists see as the biggest opportunities—and challenges—of time-limited treatment for CLL in previously untreated patients? Five Canadian hematologists with expertise in CLL recently sharedtheir perspectives which are summarized in a patient-friendly articlepublished in Current Oncology September 2025.
Treatment approaches for CLL have evolved over time. In the past, many patients received chemotherapy for a set time period as their first treatment. Ten years ago, targeted therapies were introduced, starting with BTK inhibitors, which are taken continuously for as long as they remain effectiveor until they cause intolerable side effects. These include Ibrutinib, Acalabrutinib and Zanubrutinib.
Fixed-duration novel treatments have also appeared: therapy is given for a defined length of time (often around one year), with the goal of getting the disease under very good control so treatment can stop and patients can be monitored.
Introduced a few years after Ibrutinib, Venetoclax plus Rituximab or Obinutuzumab has been the only fixed-duration treatment available for many years. This changed in 2025, when the combination of Ibrutinib and Venetoclax for first–line treatment became available in many provinces. The combination of Acalabrutinib plus Venetoclax has also recently been approved and should become available in the coming year.
These new first–line, fixed-duration regimens are all-oral medications (i.e. taken as pills), which do not require hospital visits for the treatment to be administered (which are necessary for the Obinutuzumab or Rituximab infusions that are combined with Venetoclax).
The following highlights reflect what Canadian hematologists are seeing in practice.
Many of the benefits of fixed-duration therapy relate to how treatment is experienced by patients:
- A defined treatment period and time off treatment
The newest all-oral fixed-duration therapies do not require frequent clinic visits and allow patients to stop treatment and enjoy time without daily medication. Experts noted this time off treatment may help people return to more normal routines, such as work, travel, or focusing on other aspects of their health. - Aiming for deep remission
These regimens are designed to achieve very strong responses, so treatment can safely pause while keeping CLL under control. - Side effects have an endpoint
Knowing that treatment will end can make it easier for some patients to cope with side effects. - Less chance of developing resistance to treatment
The shorter length of treatment and the combination of two different drugs reduce the chance that a patient’s CLL will become resistant to treatment. - Retreatment
Patients can be retreated with a fixed–duration regimen should their CLL return. - Cost to the health system
It is likely that the overall cost of a fixed–duration regimen is significantly lower than that of continuous treatment.
At the same time, experts highlighted important considerations when these therapies are used in practice across Canada:
- Continuous therapy remains an important option
Ongoing treatments (such as BTK inhibitors like ibrutinib or acalabrutinib) are still the right choice for some patients, particularly those with higher-risk disease (e.g. 17p or TP53 mutations), people who live farther from treatment centres or may find frequent visits difficult, or for those who feel more comfortable staying on ongoing therapy rather than stopping treatment. - Access varies across Canada
Where you live can affect whether fixed-duration therapies are available, due to provincial funding decisions and differences in how quickly new treatments are approved and covered. Even with their benefits, these treatments must fit within funding decisions and healthcare system capacity. - Shared decision-making is essential
The choice of treatment is not only a medical decision, making open discussion with the care team key. Consideration needs to be given to personal preferences, work responsibilities, personal commitments and travel requirements. Treatment funding is another factor, whether through the health system or a patient’s private insurance plan, should they have one. The article shares what patients should expect from a treatment discussion with their doctor.
Overall, Canadian hematologists view fixed-duration treatment as a meaningful advance in CLL care—one that expands choice and offers the possibility of time off therapy. While challenges remain in ensuring equal access across Canada, this approach represents another valuable tool to help tailor treatment to each patient.
This article is written in plain language and does not require technical knowledge to be understood. You can read it here.
For more information on this topic, visit the Decision to Treat and Treatment Options, and Treatment Access sections of CLL Canada’s Information and Resource Centre.